Abbott Laboratories (BVL:ABT)

Market Cap	659.43B -20.2%
Revenue (ttm)	149.13B +5.7%
Net Income	21.95B -51.3%
EPS	12.51 -51.3%
Shares Out	n/a
PE Ratio	30.05
Forward PE	19.83
Dividend	8.44 (6.42%)
Ex-Dividend Date	Jan 15, 2026

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	131.60
Day's Range	n/a
52-Week Range	123.79 - 131.60
Beta	n/a
RSI	78.74
Earnings Date	Jan 22, 2026

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1888
• Employees: 114,000
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: ABT

Financial Performance

In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.

Financial numbers in USD